Last reviewed · How we verify

NCT06214533: CEBOIDS

Celiac plExus Block to Reduce OpioID Consumption Following Hepato-pancreato-biliary Mini-invasive Surgery

Status unknown NA Last updated 19 January 2024
What this trial tests

NA trial testing Ropivacaine 0.5% in Pancreatic Ductal Adenocarcinoma in 60 participants. Status unknown.

Timeline
1 March 2024
Primary endpoint
31 August 2025
31 December 2025

Quick facts

Lead sponsorSixth Affiliated Hospital, Sun Yat-sen University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment60
Start date1 March 2024
Primary completion31 August 2025
Estimated completion31 December 2025

Drugs / interventions tested

Conditions studied

Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University

Who can join

18 and older, any sex, with Pancreatic Ductal Adenocarcinoma or Liver, Cancer of, Primary Resectable. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to assess the efficacy of intraoperative celiac plexus block (CPB) to reduce opioid consumption following laparoscopic hepato-pancreato-biliary surgery

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ropivacaine 0.5%

Trials testing the same drug.

Other recruiting trials for Pancreatic Ductal Adenocarcinoma

Currently open trials in the same condition.

Other Sixth Affiliated Hospital, Sun Yat-sen University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06214533.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing